Spero Therapeutics (SPRO) Given a $30.00 Price Target at Oppenheimer
Spero Therapeutics (NASDAQ:SPRO) has been assigned a $30.00 target price by Oppenheimer in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. Oppenheimer’s target price suggests a potential upside of 177.26% from the company’s previous close.
Several other equities analysts also recently issued reports on SPRO. Cowen began coverage on Spero Therapeutics in a research report on Monday, November 27th. They issued an “outperform” rating on the stock. Stifel Nicolaus began coverage on Spero Therapeutics in a research report on Monday, November 27th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Bank of America began coverage on Spero Therapeutics in a research report on Monday, November 27th. They issued a “neutral” rating on the stock.
Spero Therapeutics (SPRO) opened at $10.82 on Monday. Spero Therapeutics has a 12-month low of $9.84 and a 12-month high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $0.20 million. research analysts anticipate that Spero Therapeutics will post -6.35 EPS for the current year.
In other news, Director Casper Breum bought 214,285 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,999,990.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joel Sendek bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $70,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 649,356 shares of company stock worth $9,090,984. 13.90% of the stock is owned by insiders.
Spero Therapeutics Company Profile
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.